Meridian Bioscience, Inc.

LSE:0K0K Stock Report

Market Cap: US$1.5b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Meridian Bioscience Past Earnings Performance

Past criteria checks 1/6

Key information

25.3%

Earnings growth rate

24.7%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate13.0%
Return on equity11.5%
Net Margin12.7%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Meridian Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0K0K Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 22333428824
30 Jun 22344439024
31 Mar 22339628624
31 Dec 21313608024
30 Sep 21318717624
30 Jun 21306717625
31 Mar 21327877625
31 Dec 20299707425
30 Sep 20254467124
30 Jun 20240446822
31 Mar 20204216420
31 Dec 19197196119
30 Sep 19201246218
30 Jun 19203266216
31 Mar 19207276416
31 Dec 18213266816
30 Sep 18214247017
30 Jun 18210246918
31 Mar 18209186817
31 Dec 17206226617
30 Sep 17201226316
30 Jun 17198216315
31 Mar 17199306315
31 Dec 16195306114
30 Sep 16196325914
30 Jun 16195355813
31 Mar 16192365513

Quality Earnings: 0K0K has a large one-off loss of $21.2M impacting its September 30 2022 financial results.

Growing Profit Margin: 0K0K's current net profit margins (12.7%) are lower than last year (22.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0K0K's earnings have grown significantly by 25.3% per year over the past 5 years.

Accelerating Growth: 0K0K's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 0K0K had negative earnings growth (-40.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (-43.4%).


Return on Equity

High ROE: 0K0K's Return on Equity (11.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/02/01 00:16
End of Day Share Price 2023/01/26 00:00
Earnings2022/09/30
Annual Earnings2022/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Meridian Bioscience, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Mark MassaroCanaccord Genuity
Zarak KhurshidCaris & Company